Inverness closes Cholestech buy:
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations (IMI) has completed its acquisition of the heart disease diagnostics specialist Cholestech in a stock-for-stock merger. The deal, which closed September 12, saw one Cholestech share exchanged for 0.43642 IMI shares. The deal was completed through the merger of one of IMI's wholly-owned subsidiaries with and into Hayward, California-based Cholestech. This is IMI's fifth purchase of the year; it most recently closed a deal for protein-based diagnostics specialist Matritech (see Clinica No 1271, p 3).